![]() ![]() 5 Multiple studies have used MTX monotherapy in their control-arm in randomised controlled trials for tumour necrosis factor inhibitor (TNFi) therapy in PsA or have investigated the MTX response in an observational cohort, with a percentage of patients reaching MDA varying from 18% to 29%. Furthermore, in the TIght COntrol of inflammation in Psoriatic Arthritis (TICOPA) trial, which compared standard care with treat-to-target therapy strategies for PsA, 4 only 22.4% of the patients achieved minimal disease activity (MDA) after 12 weeks of MTX monotherapy. However, the MIPA trial did not use the optimal doses of MTX, and its results, therefore, are heavily debated. Until now, the only randomised controlled trial, the Methotrexate in Psoriatic Arthritis (MIPA) trial, 3 found no significant effect of MTX monotherapy on several response criteria. Both current EULAR and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis guidelines advise methotrexate (MTX) as first-line therapy for PsA, 1 2 despite lacking clear evidence, but due to positive expert experience and limitations of available studies. Inadequately treated, PsA can lead to progressive joint damage and disability. Received: Ma| Accepted: Ap| Published: April 25, 2015Ĭitation: Wang C, Chen Z, Du G, Wang T, Yang W, et al.Psoriatic arthritis (PsA) is a musculoskeletal disease associated with psoriasis presenting with any or all of peripheral arthritis, axial disease, dactylitis, enthesitis, in addition to skin and nail disease. (2015) Outcomes of Two Different Meshes for Treatment of POP with a Concomitant Midurethral Sling for SUI: a Retrospective Cohort Study at 2 Years Postoperatively. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Patients had pelvic organ prolapse (POP) often suffered stress urinary incontinence (SUI) simultaneously. We evaluated the outcomes of two different kits, Prosima and Avaulta pelvic repair systems, with a concomitant midurethral sling by treating the disease and compared the efficacies in a single center.Ī retrospective cohort study involving 57 consecutive patients underwent either of the two kits followed by tension-free vaginal transobturator tape (TVT-O). ![]() The combined surgeries were performed between October 2010 and January 2012. Women who complained bothersome POP had stage II or higher prolapse of anterior vaginal wall were included. All patients were assessed by POP-Q for anatomy, questionnaires for pelvic symptoms and sexual function at 2 years after the surgery. Perioperative outcomes and complications were also recorded. ![]() Of 57 women, 29 underwent Prosima and 28 underwent Avaulta meshes procedures. The basic patient demographics and perioperative characteristics were similar between two groups. The number of success were 28 versus 26 (P=0.53) at 1 month and 27 versus 26 (P=0.97) at 2 years of Prosima and Avaulta groups, respectively. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |